David Baxter PhD
Late Founder
Glutamate elevated in brains of mood disorder patients
By Andrew Czyzewski
27 November 2007
Biol Psychiatry 2007; 62: 1310-1316
Patients with bipolar disorder and major depression have elevated glutamate levels in the frontal cortex compared with mentally healthy controls, say the results of a postmortem study.
Glutamate is the major excitatory neurotransmitter in the cerebral cortex and is thought to play a role in major mental disorders, explain Kenji Hashimoto (Chiba University Center for Forensic Mental Health, Japan) and colleagues in the journal Biological Psychiatry.
Glutamate antagonists such as phencyclidine (PCP) and ketamine produce a psychotic state that mimics schizophrenia, leading some scientists to suggest that glutamate plays a role in the disease.
On the other hand it remains unclear whether glutamatergic neurotransmission plays a role in mood disorders such as bipolar disorder and major depression.
Post mortem brains are critical for examining molecular changes associated with the pathophysiology of mental disorders, but studies have so far provided conflicting results, say Hashimoto and colleagues.
This may be partly due to wide variations in the time between death and the extraction of tissue - known as the post mortem interval (PMI) - which can have a pronounced effect on glutamate levels. Unfortunately, such variations are often unavoidable when using biological samples.
To model variations in the PMI of human tissue, the researchers first examined glutamate levels in the frontal cortex of mouse brains taken at 6, 12, 24, 36, 48, 60, and 72 hours after death.
Hashimoto and colleagues then analyzed glutamate levels in human post mortem frontal cortex adjusting for PMI based on the mouse data.
Tissue samples were taken from 15 patients with schizophrenia, 15 patients with bipolar disorder, 15 patients with major depression, and 15 mentally healthy controls.
The frontal cortex of bipolar patients had, on average, 15.33 nmol of glutamate per mg of brain tissue - significantly higher than the 10.68 nmol/mg found in the brains of mentally healthy controls.
This finding is consistent with the observation that mood-stabilizing drugs used in the treatment of bipolar disorder exert neuroprotective effects against glutamate-induced excitotoxicity in neuron cultures, say the researchers.
They found that patients with major depression also had elevated levels of glutamate in the frontal cortex at 14.09 nmol/mg. Contrary to their predictions, glutamate was not, however, elevated in the brains of patients with schizophrenia.
Based on these findings, the team concludes that increased glutamate may lead to an increase in neuronal cell death contributing to the pathophysiology of mood disorders.
Abstract
By Andrew Czyzewski
27 November 2007
Biol Psychiatry 2007; 62: 1310-1316
Patients with bipolar disorder and major depression have elevated glutamate levels in the frontal cortex compared with mentally healthy controls, say the results of a postmortem study.
Glutamate is the major excitatory neurotransmitter in the cerebral cortex and is thought to play a role in major mental disorders, explain Kenji Hashimoto (Chiba University Center for Forensic Mental Health, Japan) and colleagues in the journal Biological Psychiatry.
Glutamate antagonists such as phencyclidine (PCP) and ketamine produce a psychotic state that mimics schizophrenia, leading some scientists to suggest that glutamate plays a role in the disease.
On the other hand it remains unclear whether glutamatergic neurotransmission plays a role in mood disorders such as bipolar disorder and major depression.
Post mortem brains are critical for examining molecular changes associated with the pathophysiology of mental disorders, but studies have so far provided conflicting results, say Hashimoto and colleagues.
This may be partly due to wide variations in the time between death and the extraction of tissue - known as the post mortem interval (PMI) - which can have a pronounced effect on glutamate levels. Unfortunately, such variations are often unavoidable when using biological samples.
To model variations in the PMI of human tissue, the researchers first examined glutamate levels in the frontal cortex of mouse brains taken at 6, 12, 24, 36, 48, 60, and 72 hours after death.
Hashimoto and colleagues then analyzed glutamate levels in human post mortem frontal cortex adjusting for PMI based on the mouse data.
Tissue samples were taken from 15 patients with schizophrenia, 15 patients with bipolar disorder, 15 patients with major depression, and 15 mentally healthy controls.
The frontal cortex of bipolar patients had, on average, 15.33 nmol of glutamate per mg of brain tissue - significantly higher than the 10.68 nmol/mg found in the brains of mentally healthy controls.
This finding is consistent with the observation that mood-stabilizing drugs used in the treatment of bipolar disorder exert neuroprotective effects against glutamate-induced excitotoxicity in neuron cultures, say the researchers.
They found that patients with major depression also had elevated levels of glutamate in the frontal cortex at 14.09 nmol/mg. Contrary to their predictions, glutamate was not, however, elevated in the brains of patients with schizophrenia.
Based on these findings, the team concludes that increased glutamate may lead to an increase in neuronal cell death contributing to the pathophysiology of mood disorders.
Abstract